Teva Fined $500M for Patent Infringement
This is a news story, published by Yahoo Finance (Canada), that relates primarily to European Commission news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance (Canada) news
For more news from Yahoo Finance (Canada), you can click here:
more news from Yahoo Finance (Canada)About the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Israeli generic drugmaker Teva. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest pharmaceutical firm news, patent protection news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
blockbuster MS drug CopaxoneAssociated Press News
•EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
82% Informative
European Commission says it has fined Israeli generic drugmaker Teva more than 460 million euros ( $500 million ) The pharmaceutical firm “misused the patent system to artificially extend patent protection” for its blockbuster MS drug Copaxone .
To do that, Teva conducted a “disparagement campaign” against Synthon , the only other company with an authorized drug in Europe containing glatiramer acetate.
VR Score
87
Informative language
89
Neutral language
48
Article tone
formal
Language
English
Language complexity
70
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links